Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...

The practice of selectively removing a few lymph nodes, instead of removing all axillary, or armpit, lymph nodes, is still relatively new. The number of women who undergo sentinel lymph node biopsy ...

Please provide your email address to receive an email when new articles are posted on . Sentinel lymph node biopsy (SLNB) is a low-risk procedure that can reduce the need for complete lymph node ...

10-year outcomes of breast cancer patients with histologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. This is an ASCO Meeting ...

Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract ...

DALLAS – Oct. 1, 2013 – A conservative approach to removing lymph nodes is associated with less harm for breast cancer patients and often yields the same results as more radical procedures, ...

Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...

Future breast cancer treatment options may not only increase patients’ survival but also reduce or eliminate their need for surgery altogether, says breast cancer surgeon Sara Javid, MD, Fred ...

Lymph node status in stage I hormone receptor-positive/HER2-negative breast cancer was not a good indicator of genetic-risk scores that would qualify older women for ...